Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
$1.65
-1.2%
$1.96
$1.12
$4.20
$122.66M0.94244,968 shs177,400 shs
Organogenesis stock logo
ORGO
Organogenesis
$3.61
+2.0%
$3.62
$2.28
$6.71
$449.06M1.631.14 million shs910,163 shs
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$10.74
-0.5%
$10.15
$6.65
$12.61
$734.33M0.026,042 shs4,524 shs
Valneva SE Sponsored ADR stock logo
VALN
Valneva
$5.82
+5.8%
$6.29
$3.62
$8.66
$468.21M1.8142,473 shs10,389 shs
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
-1.20%-2.94%-6.78%-27.95%+17.02%
Organogenesis stock logo
ORGO
Organogenesis
+1.98%+10.40%+21.55%-19.78%+39.92%
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
-1.92%-4.02%-0.42%+28.22%+32.76%
Valneva SE Sponsored ADR stock logo
VALN
Valneva
+3.65%+1.75%-9.47%-19.83%-21.03%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
1.4989 of 5 stars
3.31.00.00.00.00.01.3
Organogenesis stock logo
ORGO
Organogenesis
4.5122 of 5 stars
3.33.00.04.32.74.20.6
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
2.3357 of 5 stars
3.53.00.00.02.90.00.6
Valneva SE Sponsored ADR stock logo
VALN
Valneva
2.5545 of 5 stars
3.55.00.00.02.00.80.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
2.50
Moderate Buy$6.50293.94% Upside
Organogenesis stock logo
ORGO
Organogenesis
2.50
Moderate Buy$5.5052.35% Upside
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
3.00
Buy$30.00179.33% Upside
Valneva SE Sponsored ADR stock logo
VALN
Valneva
3.00
Buy$15.50166.32% Upside

Current Analyst Ratings Breakdown

Latest IKT, PHAR, VALN, and ORGO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/8/2025
Valneva SE Sponsored ADR stock logo
VALN
Valneva
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$15.00 ➝ $14.00
4/15/2025
Valneva SE Sponsored ADR stock logo
VALN
Valneva
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$17.00 ➝ $17.00
4/9/2025
Valneva SE Sponsored ADR stock logo
VALN
Valneva
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$17.00 ➝ $17.00
3/31/2025
Valneva SE Sponsored ADR stock logo
VALN
Valneva
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$17.00 ➝ $17.00
3/28/2025
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingNeutral ➝ Neutral
(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
$260K471.79N/AN/A$1.78 per share0.93
Organogenesis stock logo
ORGO
Organogenesis
$482.04M0.95$0.21 per share16.97$2.09 per share1.73
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
$297.20M2.46$0.07 per share145.61$3.25 per share3.30
Valneva SE Sponsored ADR stock logo
VALN
Valneva
$183.52M2.70$0.10 per share56.31$2.41 per share2.41
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
-$19.03M-$2.67N/AN/AN/AN/A-350.63%-201.82%N/A
Organogenesis stock logo
ORGO
Organogenesis
$860K-$0.17N/AN/AN/A-3.46%-4.00%-2.26%8/6/2025 (Estimated)
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
-$11.84M-$0.20N/A358.00N/A-4.14%-6.01%-3.23%7/30/2025 (Estimated)
Valneva SE Sponsored ADR stock logo
VALN
Valneva
-$13.25M-$1.19N/AN/AN/A-43.08%-43.05%-16.23%8/12/2025 (Estimated)

Latest IKT, PHAR, VALN, and ORGO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/8/2025Q1 2025
Organogenesis stock logo
ORGO
Organogenesis
$0.04-$0.13-$0.17-$0.17$90.77 million$86.69 million
5/8/2025Q1 2025
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
-$0.25-$0.22+$0.03-$0.22$67.74 million$79.09 million
5/7/2025Q1 2025
Valneva SE Sponsored ADR stock logo
VALN
Valneva
-$0.40-$0.13+$0.27-$0.13$41.80 million$51.79 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
N/AN/AN/AN/AN/A
Organogenesis stock logo
ORGO
Organogenesis
N/AN/AN/AN/AN/A
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
N/AN/AN/AN/AN/A
Valneva SE Sponsored ADR stock logo
VALN
Valneva
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
N/A
0.85
0.85
Organogenesis stock logo
ORGO
Organogenesis
N/A
4.12
3.67
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
0.39
2.76
2.00
Valneva SE Sponsored ADR stock logo
VALN
Valneva
0.92
2.70
2.12

Institutional Ownership

CompanyInstitutional Ownership
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
3.81%
Organogenesis stock logo
ORGO
Organogenesis
49.57%
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
0.03%
Valneva SE Sponsored ADR stock logo
VALN
Valneva
11.39%

Insider Ownership

CompanyInsider Ownership
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
7.30%
Organogenesis stock logo
ORGO
Organogenesis
33.00%
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
2.07%
Valneva SE Sponsored ADR stock logo
VALN
Valneva
14.91%
CompanyEmployeesShares OutstandingFree FloatOptionable
Inhibikase Therapeutics, Inc. stock logo
IKT
Inhibikase Therapeutics
674.34 million66.18 millionNot Optionable
Organogenesis stock logo
ORGO
Organogenesis
950126.85 million84.99 millionOptionable
Pharming Group N.V. Sponsored ADR stock logo
PHAR
Pharming Group
28068.03 million66.62 millionNot Optionable
Valneva SE Sponsored ADR stock logo
VALN
Valneva
70085.09 million72.41 millionNot Optionable

Recent News About These Companies

US Advises Older Travelers to Avoid Chikungunya Vaccine

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Inhibikase Therapeutics stock logo

Inhibikase Therapeutics NYSE:IKT

$1.65 -0.02 (-1.20%)
Closing price 06/26/2025 04:00 PM Eastern
Extended Trading
$1.65 0.00 (0.00%)
As of 06/26/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapeutics for Parkinson's disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson's disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is headquartered in Atlanta, Georgia.

Organogenesis stock logo

Organogenesis NASDAQ:ORGO

$3.61 +0.07 (+1.98%)
Closing price 06/26/2025 04:00 PM Eastern
Extended Trading
$3.78 +0.17 (+4.71%)
As of 08:19 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage. Its products also include FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; PuraPly MZ, a micronized particulate version of PuraPly for the management of open wounds in the surgical setting; and CYGNUS Dual, a dehydrated placental tissue preserved to retain the ECM scaffold. The company's pipeline products include ReNu, a cryopreserved suspension used to support healing of soft tissues; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales representives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.

Pharming Group stock logo

Pharming Group NASDAQ:PHAR

$10.74 -0.05 (-0.46%)
Closing price 06/26/2025 03:56 PM Eastern
Extended Trading
$11.24 +0.50 (+4.65%)
As of 07:20 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

Valneva stock logo

Valneva NASDAQ:VALN

$5.82 +0.32 (+5.82%)
As of 06/26/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine. The company also develops VLA15, a vaccine candidate, which is in Phase III clinical trial against Borrelia, the bacterium that causes Lyme disease; VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus; VLA1554, a vaccine candidate targeting human metapneumovirus; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is based in Saint-Herblain, France.